Caroline (Caro) Van Hove , , , Executive Chair

View bioHide bio

Caroline Van Hove joined Sientra’s Board in January 2020 and was named Executive Chair in November 2020. Ms. Van Hove is a global commercial leader with over 20 years of diverse experience in the pharmaceutical, consumer and medical device industry. Her experience spans North America to Europe, Africa, the Middle East to Asia Pacific and Latin America.

Ms. Van Hove is currently President and CEO of a venture-backed, clinical-stage medical aesthetics company, and previously held several commercial leadership roles at both start-up and large-cap companies. Ms. Van Hove previously served as Chief Commercial Officer of Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on therapies in immunology and inflammation. Prior to Sienna, Ms. Van Hove was Senior Vice President of International Strategic Marketing at Allergan, where she oversaw commercial operations for the medical aesthetics, eye care and specialty care franchises. Previously, Ms. Van Hove managed sales & marketing, customer service and customer excellence in Europe, Africa and the Middle East and led Allergan’s international medical aesthetics operations. Ms. Van Hove also served as part of Allergan’s Global Operations & International Leadership Teams.

Ms. Van Hove also serves on the Board of Directors of Mission Plasticos, a global non-profit dedicated to providing reconstructive surgery to children in need.

Ron Menezes , , , Director,
President and CEO Sientra, Inc

View bioHide bio

Ron Menezes joined Sientra in November 2020 as President and Chief Executive Officer. Ron’s most recent experience includes serving as President and General Manager for Almirall U.S. – Dermatology, where he led exceptional growth and profitability improvements, returning the U.S. division to profitability. Ron was also part of the team that successfully acquired Allergan’s dermatology assets in 2018. In 2019, he led the launch of a new molecule for the treatment of acne that far exceeded revenue goals by strategically focusing on improving patients’ access to the product. Prior to Almirall, Ron was the Vice President of Sales and Marketing for Dermatology at Allergan, leading the team to more than 20% yearly growth between 2013 and 2015. The growth was driven by increased direct-to-consumer advertising and expanding the promotion of a 20-year-old topical product for acne. As a head of sales for SkinMedica, Latisse and Medical Dermatology, Ron was part of the commercial team that successfully launched a new direct-to-physician sunscreen product. While at SkinMedica, he focused on expanding national accounts that were responsible for driving most of the growth in 2015. Ron has also held key leadership responsibilities at Abbott, Astellas Pharma – U.S., Pfizer and Eli Lilly. Ron holds a B.S. in International Business from Brigham Young University and earned a certificate in Health Care Management from the University of Utah.

Nori Ebersole , , , Director

View bioHide bio

Nori Ebersole has served as a director of the company since July 2021. She currently serves as the Chief People Officer at Prometheus Biosciences, Inc. (Nasdaq RXDX) based in San Diego, California since April 2021. Prior to that, from December 2017 to April 2021, Ms. Ebersole served as EVP & Chief Human Resources Officer for Urovant Sciences, Inc (Nasdaq UROV), until its merger with Sumitomo Dainippon. She was instrumental in the completion of Urovant’s IPO, building the executive, senior leadership and board teams, commercial launch, obtained Orange County Business Journals Best Companies to Work for in 2021 and received the 2020 National Human Resources Associations, Orange County, small companies, HR Executive of the Year award. In addition, she also led the development and execution of Urovant’s diversity, equity and inclusion strategy, employment brand (Powered By People And Possibilities™), talent acquisition, culture, mission, vision and values strategies. Prior to Urovant, Ms. Ebsersole was the Chief Human Resources Officer at Paul Hastings, LLP from September 2015 to December 2017. She also served 18 years at Allergan Inc, (NYSE; AGN now Abbvie) from April 1994 to June 2015, until their sale to Actavis for $70.5B. While at Allergan, Ms. Ebersole last served as Vice President, Human Resources, partnering with senior executives globally on various key initiatives in commercial, R&D, and additional strategic initiatives to include the successful U.S. launch of BOTOX Cosmetics in 2002. Ms. Ebersole earned a B.S. in Business Administration from the University of Southern California Marshall School of Business and serves on the board of Big Brothers, Big Sisters of Orange County a not-for-profit charitable organization supporting children at risk.

Dr. Irina Erenburg , , , Director

View bioHide bio

Dr. Irina Erenburg has served as a director of the company since July 2021. She is Founder, President & CEO of Blossom Innovations, LLC. Blossom is a groundbreaking company dedicated to the discovery and development of new clinical breakthroughs in Dermatology & Aesthetics. Dr. Erenburg is a successful serial entrepreneur with extensive experience in innovation business leadership. She is a co-founder and board member of R2 Technologies, Inc., AVAVA, Inc. and Soltego, Inc. Prior to leading Blossom Innovations, she was the Director of Strategic Transactions at the Partners HealthCare Office of Innovations, Boston’s largest hospital network and a teaching affiliate of Harvard University. There, she was responsible for execution and management of high-value deals and launch of several successful start-ups, including Zeltiq Aesthetics. Dr. Erenburg holds a Ph.D. in Biomedical Science from the Mount Sinai School of Medicine in NY. Dr. Irina Erenburg is Founder, President & CEO of Blossom Innovations, LLC. Blossom is a groundbreaking company dedicated to the discovery and development of new clinical breakthroughs in Dermatology & Aesthetics. Dr. Erenburg is a successful serial entrepreneur with extensive experience in innovation business leadership. She is a co-founder and board member of R2 Technologies, Inc., AVAVA, Inc. and Soltego, Inc. Prior to leading Blossom Innovations, she was the Director of Strategic Transactions at the Partners HealthCare Office of Innovations, Boston’s largest hospital network and a teaching affiliate of Harvard University. There, she was responsible for execution and management of high-value deals and launch of several successful start-ups, including Zeltiq Aesthetics. Dr. Erenburg holds a Ph.D. in Biomedical Science from the Mount Sinai School of Medicine in NY.

Mary Fisher , , , Director

View bioHide bio

Mary Fisher has served as a director of the Company since January 2019. Ms. Fisher currently serves as Chief Executive Officer, Chair and Board Director at Colorescience, a science-based skincare company and former division of SkinMedica, Inc. While at SkinMedica, she served as Chief Executive Officer from 2008 to 2012, when she led the successful sale of the company to Allergan, Inc. Prior to joining SkinMedica, Ms. Fisher served as the Chief Operating Officer of Acorda Therapeutics, a biotechnology company. She has previously held management and leadership positions at Cephalon, Immunex, and Boehringer Ingelheim. She previously served on the Board of Directors at ZELTIQ Aesthetics, Inc. and Ovascience and currently sits on the Board of MDRejuvena. In 2013, Ms. Fisher was honored as Ernst & Young’s Entrepreneur of the Year for San Diego and also received the EY Venture Capital Award of Excellence. Ms. Fisher was also named a finalist for Most Admired CEO by the San Diego Business Journal in 2018.

Philippe Schaison , , Dr. , , Director

View bioHide bio

Philippe Schaison has served as a director of the Company since February 2017. Mr. Schaison has extensive experience leading global aesthetic organizations. Mr. Schaison currently serves as CEO and member of the board of Soltega, a biopharmaceutical innovator dedicated to leveraging the skin’s pigmentation power for therapeutic and aesthetic applications. Mr. Schaison was formerly the CEO of Syneron Candela North America and Global Executive Vice President Strategy and Business Development from November 2016 until its acquisition by Apax Partners in April 2017. Prior to that, Mr. Schaison served as President of Allergan’s U.S. aesthetic and dermatology business from September 2013 until October 2016. In that position, he led the Facial Aesthetic, Plastic and MedDerm/Skin Medical business unit, an organization of over 2,000 professionals focused on the company’s Botox® and fillers franchises. Prior to joining Allergan, Mr. Schaison served as President, World Wide Travel Retail & Regional President, LATAM and MEA, at Clarins in New York from 2010 to August 2013. Earlier, Mr. Schaison served as CEO for Aesthetic Factors, a manufacturer of point-of-care systems for regenerative medicines and as Vice President of Global Skin Care for Johnson & Johnson, with P&L responsibility for Aveeno, Clean & Clear, Lubriderm, and Ambi, and in executive positions at L’Oréal. Mr. Schaison sits on the Board of the Galien Foundation and SENTÉ, Inc., a privately held specialty aesthetics company. He earned his MBA (Marketing) from the Hautes Etudes Commerciales (H.E.C.) in Paris, and a Doctorate in Pharmacy (Industrial) from the University of Paris.

Nasdaq: SIEN

Stock Quote: NASD

$0.17 -0.04
Volume 3,435,111
Previous Close 0.21
Intraday High 0.20
Intraday Low 0.16
Pricing delayed 20 minutes
Price Change % Change -18.69% 52 Week High 4.94 52 Week Low 0.16 Today's Open 0.19 Feb 21, 2024 04:00 PM

Investor Contact

Sientra Investor Relations
ir@sientra.com